Renal sympathetic denervation safely reduces blood pressure in patients with treatment-resistant hypertension based on early trial evidence, though further research is needed to verify these data.
Does renal sympathetic denervation reduce blood pressure in patients with treatment-resistant hypertension?
Renal sympathetic denervation represents a promising interventional approach for managing treatment-resistant hypertension, though further research is required to verify early trial data.
UNLABELLED: Hypertension is a major public health concern that is increasing in prevalence. Lifestyle and pharmacological management are not always sufficient to control blood pressure and treatment-resistant hypertension is a recognized clinical challenge. Renal sympathetic denervation (RSD) represents a new frontier in the treatment of resistant hypertension. RESULTS: from the Symplicity HTN-1 and HTN-2 trials have demonstrated evidence that suggests RSD can safely reduce blood pressure in patients with this condition. More research is needed to verify these data, clarify unanswered questions and assess future applications of RSD. This review provides a detailed overview on the history of hypertension, treatment-resistant hypertension, the rationale behind RSD, current evidence and potential future applications of RSD. An overview of current and upcoming RSD devices is also included.
Mafeld et al. (Tue,) conducted a review in Treatment-resistant hypertension. Renal sympathetic denervation (RSD) was evaluated. Renal sympathetic denervation safely reduces blood pressure in patients with treatment-resistant hypertension based on early trial evidence, though further research is needed to verify these data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: